Speedy E6 Inhibitors
Speedy E6 inhibitors belong to a class of chemical compounds that have been characterized for their specific interaction with a biological entity known as Speedy E6. This interaction is primarily biochemical, focusing on the inhibition of the activity of Speedy E6. These inhibitors are designed based on the understanding of the molecular structure and the biochemical pathways involving Speedy E6. The inhibitors typically work by binding to the active site or another critical region of Speedy E6, thereby preventing it from performing its normal biological function. This binding can be competitive, non-competitive, or uncompetitive depending on the structural design of the inhibitor and its mode of interaction with Speedy E6. The design of Speedy E6 inhibitors is a sophisticated process that involves the identification of key molecular motifs that are essential for the activity of Speedy E6 and the subsequent synthesis of compounds that can mimic or interact with these motifs.
The development of Speedy E6 inhibitors encompasses a variety of disciplines, including chemistry, biology, and computational modeling. Chemists play a crucial role in synthesizing inhibitors that not only possess the ability to bind to Speedy E6 but also possess desirable physical and chemical properties to ensure stability and specificity. The specificity of Speedy E6 inhibitors is paramount, as it determines the selectivity of the compound for Speedy E6 over other biological molecules. Computational models are used to predict how these compounds might interact with Speedy E6 and to design inhibitors that have optimal binding characteristics. The structural aspects of Speedy E6 inhibitors are diverse, with some inhibitors resembling substrates or products of the Speedy E6-mediated process, while others are designed based on the unique topography of the Speedy E6's active site. Understanding the dynamic nature of the interaction between Speedy E6 and its inhibitors is also critical, as it can influence the development of new compounds with improved properties.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib is a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. Speedy E6, being involved in cell cycle regulation, could be functionally inhibited by palbociclib through the suppression of CDK4/6 activity, which are essential for the G1-S phase transition that Speedy E6 is likely involved in. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
Ribociclib selectively inhibits CDK4/6, similar to palbociclib and trilaciclib. This inhibition leads to cell cycle arrest at the G1 phase and potentially reduces the functional activity of Speedy E6, which is closely tied to cell cycle progression. | ||||||
N-[5-[(4-Ethyl-1-piperazinyl)methyl]-2-pyridinyl]-5-fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl]-2-pyrimidinamine Methanesulfonate | 1231930-82-7 | sc-496536 | 2.5 mg | $398.00 | ||
Abemaciclib selectively inhibits CDK4/6, leading to G1 phase cell cycle arrest. The action of abemaciclib would oppose the function of Speedy E6 if Speedy E6 promotes cell cycle progression. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $254.00 | 41 | |
Flavopiridol inhibits various CDKs including CDK1, CDK2, CDK4, and CDK6. Inhibition of these kinases is likely to interfere with the function of Speedy E6 if it is involved in cell cycle regulation. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $92.00 $260.00 | 42 | |
Roscovitine is a CDK inhibitor that targets CDK1, CDK2, CDK5, CDK7, and CDK9, which are involved in transcription and cell cycle control. This broad inhibition can indirectly decrease Speedy E6 activity if its function is cell cycle-dependent. | ||||||
Dinaciclib | 779353-01-4 | sc-364483 sc-364483A | 5 mg 25 mg | $242.00 $871.00 | 1 | |
Dinaciclib is a potent CDK inhibitor with activity against CDK1, CDK2, CDK5, and CDK9. It may inhibit the function of Speedy E6 by preventing cell cycle progression and transcriptional regulation. | ||||||
PHA-848125 | 802539-81-7 | sc-364581 sc-364581A | 5 mg 10 mg | $304.00 $555.00 | ||
Milciclib inhibits various CDKs and could lead to inhibition of Speedy E6 activity by arresting cells in the G1 phase of the cell cycle if Speedy E6 is involved in the transition through this phase. | ||||||
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $67.00 $306.00 | 2 | |
Alsterpaullone inhibits CDK1 and CDK5, as well as glycogen synthase kinase-3 (GSK-3). If Speedy E6 is involved in GSK-3-associated pathways, its activity would be indirectly reduced by alsterpaullone. | ||||||
Purvalanol A | 212844-53-6 | sc-224244 sc-224244A | 1 mg 5 mg | $71.00 $291.00 | 4 | |
Purvalanol A is a potent inhibitor of CDKs, particularly CDK1, CDK2, and CDK5. Inhibition of these kinases can lead to decreased Speedy E6 activity if Speedy E6 is involved in cell cycle checkpoints controlled by these kinases. | ||||||
AZD 5438 | 602306-29-6 | sc-361115 sc-361115A | 10 mg 50 mg | $205.00 $865.00 | ||
AZD5438 inhibits CDK1, CDK2, and CDK9, which could result in the inhibition of Speedy E6 function by impeding cell cycle progression and transcriptional regulation if Speedy E6 is connected to these processes. | ||||||